IdentificationGeneric Name(2R)-N-HYDROXY-2-[(3S)-3-METHYL-3-{4-[(2-METHYLQUINOLIN-4-YL)METHOXY]PHENYL}-2-OXOPYRROLIDIN-1-YL]PROPANAMIDEDrugBank Accession NumberDB07145BackgroundNot AvailableTypeSmall MoleculeGroupsExperimentalStructure


3DDownload MOLSDF3D-SDFPDBSMILESInChI


 Similar StructuresStructure for (2R)-N-HYDROXY-2-[(3S)-3-METHYL-3-{4-[(2-METHYLQUINOLIN-4-YL)METHOXY]PHENYL}-2-OXOPYRROLIDIN-1-YL]PROPANAMIDE (DB07145)× CloseWeightAverage: 433.4996 Monoisotopic: 433.200156367 Chemical FormulaC25H27N3O4SynonymsNot AvailablePharmacologyIndicationNot AvailableReduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, & validate predictive machine-learning models with structured datasets.See howContraindications & Blackbox WarningsAvoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Learn more  Avoid life-threatening adverse drug events & improve clinical decision support.Learn morePharmacodynamicsNot AvailableMechanism of actionTargetActionsOrganismUDisintegrin and metalloproteinase domain-containing protein 17Not AvailableHumansAbsorptionNot AvailableVolume of distributionNot AvailableProtein bindingNot AvailableMetabolismNot AvailableRoute of eliminationNot AvailableHalf-lifeNot AvailableClearanceNot AvailableAdverse EffectsImprove decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Learn more  Improve decision support & research outcomes with our structured adverse effects data.Learn moreToxicityNot AvailablePathwaysNot AvailablePharmacogenomic Effects/ADRs 


Not AvailableInteractionsDrug Interactions 


This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist. Not AvailableFood InteractionsNot AvailableCategoriesDrug CategoriesNot AvailableChemical TaxonomyProvided by ClassyfireDescriptionThis compound belongs to the class of organic compounds known as phenylpyrrolidines. These are polycyclic aromatic compounds containing a benzene ring linked to a pyrrolidine ring through a CC or CN bond. Pyrrolidine is a five-membered saturated aliphatic heterocycle with one nitrogen atom and four carbon atoms.KingdomOrganic compoundsSuper ClassOrganoheterocyclic compoundsClassPyrrolidinesSub ClassPhenylpyrrolidinesDirect ParentPhenylpyrrolidinesAlternative ParentsQuinolines and derivatives / Phenoxy compounds / Phenol ethers / Alkyl aryl ethers / Methylpyridines / Pyrrolidine-2-ones / N-alkylpyrrolidines / Tertiary carboxylic acid amides / Pyrroles / Heteroaromatic compounds / Lactams / Azacyclic compounds / Hydrocarbon derivatives / Organic oxides / Carbonyl compounds / Organonitrogen compounds / Organopnictogen compounds


 show 7 moreSubstituents2-pyrrolidone / 3-phenylpyrrolidine / Alkyl aryl ether / Aromatic heteropolycyclic compound / Azacycle / Benzenoid / Carbonyl group / Carboxamide group / Carboxylic acid derivative / Ether / Heteroaromatic compound / Hydrocarbon derivative / Lactam / Methylpyridine / Monocyclic benzene moiety / N-alkylpyrrolidine / Organic nitrogen compound / Organic oxide / Organic oxygen compound / Organonitrogen compound / Organooxygen compound / Organopnictogen compound / Phenol ether / Phenoxy compound / Pyridine / Pyrrole / Pyrrolidone / Quinoline / Tertiary carboxylic acid amide


 show 19 moreMolecular FrameworkAromatic heteropolycyclic compoundsExternal Descriptorsquinolines, hydroxamic acid, pyrrolidin-2-ones (CHEBI:40083) Affected organismsNot AvailableChemical IdentifiersUNIINot AvailableCAS numberNot AvailableInChI KeyYDMIPBHQKFOFQW-NSYGIPOTSA-NInChIInChI=1S/C25H27N3O4/c1-16-14-18(21-6-4-5-7-22(21)26-16)15-32-20-10-8-19(9-11-20)25(3)12-13-28(24(25)30)17(2)23(29)27-31/h4-11,14,17,31H,12-13,15H2,1-3H3,(H,27,29)/t17-,25+/m1/s1IUPAC Name(2R)-N-hydroxy-2-[(3S)-3-methyl-3-{4-[(2-methylquinolin-4-yl)methoxy]phenyl}-2-oxopyrrolidin-1-yl]propanamideSMILES[H][C@](C)(N1CC[C@](C)(C1=O)C1=CC=C(OCC2=CC(C)=NC3=CC=CC=C23)C=C1)C(=O)NOReferencesGeneral ReferencesNot AvailableExternal LinksPubChem Compound6914621PubChem Substance99443616ChemSpider5290501BindingDB26526ChEBI40083ChEMBLCHEMBL148169ZINCZINC000003820969PDBe Ligand541PDB Entries2fv5Clinical TrialsClinical Trials 


PhaseStatusPurposeConditionsCountPharmacoeconomicsManufacturersNot AvailablePackagersNot AvailableDosage FormsNot AvailablePricesNot AvailablePatentsNot AvailablePropertiesStateSolidExperimental PropertiesNot AvailablePredicted PropertiesPropertyValueSourceWater Solubility0.00414 mg/mLALOGPSlogP3.8ALOGPSlogP2.97ChemaxonlogS-5ALOGPSpKa (Strongest Acidic)8.72ChemaxonpKa (Strongest Basic)5.02ChemaxonPhysiological Charge0ChemaxonHydrogen Acceptor Count5ChemaxonHydrogen Donor Count2ChemaxonPolar Surface Area91.76 Å2ChemaxonRotatable Bond Count6ChemaxonRefractivity120.08 m3·mol-1ChemaxonPolarizability47.66 Å3ChemaxonNumber of Rings4ChemaxonBioavailability1ChemaxonRule of FiveYesChemaxonGhose FilterYesChemaxonVeber's RuleNoChemaxonMDDR-like RuleYesChemaxonPredicted ADMET FeaturesPropertyValueProbabilityHuman Intestinal Absorption+0.9653Blood Brain Barrier-0.7125Caco-2 permeable-0.7048P-glycoprotein substrateSubstrate0.7943P-glycoprotein inhibitor INon-inhibitor0.5687P-glycoprotein inhibitor IIInhibitor0.9517Renal organic cation transporterNon-inhibitor0.7767CYP450 2C9 substrateNon-substrate0.8137CYP450 2D6 substrateNon-substrate0.7759CYP450 3A4 substrateSubstrate0.7324CYP450 1A2 substrateNon-inhibitor0.8444CYP450 2C9 inhibitorInhibitor0.5546CYP450 2D6 inhibitorNon-inhibitor0.7629CYP450 2C19 inhibitorNon-inhibitor0.5161CYP450 3A4 inhibitorInhibitor0.7827CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.7073Ames testNon AMES toxic0.5656CarcinogenicityNon-carcinogens0.7714BiodegradationNot ready biodegradable1.0Rat acute toxicity2.6764 LD50, mol/kg Not applicablehERG inhibition (predictor I)Weak inhibitor0.9785hERG inhibition (predictor II)Inhibitor0.5432  ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397) SpectraMass Spec (NIST)Not AvailableSpectraSpectrumSpectrum TypeSplash KeyPredicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot AvailablePredicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot AvailablePredicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot AvailablePredicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot AvailablePredicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot AvailablePredicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot AvailableTargetsBuild, predict & validate machine-learning modelsUse our structured and evidence-based datasets to unlock newinsights and accelerate drug research.Learn more  Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.Learn moreBinding Properties×PropertyMeasurementpHTemperature (°C)ReferencesIC 50 (nM)0.56N/AN/AA30775IC 50 (nM)1N/AN/AA30776 / A30777


 Details


 Binding Properties1. Disintegrin and metalloproteinase domain-containing protein 17KindProteinOrganismHumansPharmacological actionUnknownGeneral FunctionZinc ion bindingSpecific FunctionCleaves the membrane-bound precursor of TNF-alpha to its mature soluble form. Responsible for the proteolytical release of soluble JAM3 from endothelial cells surface. Responsible for the proteolyt...Gene NameADAM17Uniprot IDP78536Uniprot NameDisintegrin and metalloproteinase domain-containing protein 17Molecular Weight93020.165 DaReferencesBerman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [Article] ×Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice. Learn more   Drug created at September 15, 2010 21:19 / Updated at June 12, 2020 16:52 